

| | |
|--|-----------|
| OMB Number: | 3235-0287 |
| Estimated average burden hours per response: | 0.5 |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

| | | |
|---|--|---|
| 1. Name and Address of Reporting Person * <u>Rice William G.</u> _____ (Last) (First) (Middle) <u>C/O APTOSE BIOSCIENCES INC.</u> <u>251 CONSUMERS ROAD, SUITE 1105</u> _____ (Street) <u>TORONTO A6 M2J 4R3</u> _____ (City) (State) (Zip) | 2. Issuer Name and Ticker or Trading Symbol <u>Aptose Biosciences Inc. [APTO]</u> | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chair, President & CEO</u> |
| | 3. Date of Earliest Transaction (Month/Day/Year) <u>06/30/2026</u> | |
| | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|-----------------------|---|--|---|
| | | | Code | V | Amount | (A) or (D) | Price | | | |
| Common Shares | 06/30/2026 | | D ⁽¹⁾ | | 613,252 | D | \$1.72 ⁽²⁾ | 0 | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|-----------|--|-----------------------|---|----------------------------|--|--|---|--|
| | | | | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Employee Stock Option ("Right to Buy") | \$2 | 06/30/2026 | | D ⁽¹⁾ | | | 70,000 | ⁽³⁾ | 02/05/2034 | Common Shares | 70,000 | \$0 | 0 | D | |
| Warrants | \$0.25 | 06/30/2026 | | D ⁽¹⁾ | | | 50,000 | | 11/25/2024 11/25/2029 | Common Shares | 500,000 | \$0 | 0 | D | |
| Employee Stock Option ("Right to Buy") | \$0.66 | 06/30/2026 | | D ⁽¹⁾ | | | 400,000 | ⁽³⁾ | 01/29/2033 | Common Shares | 400,000 | \$0 | 0 | D | |
| Performance Stock Options | \$0.81 | 06/30/2026 | | D ⁽¹⁾ | | | 600,000 | ⁽³⁾ | 07/06/2032 | Common Shares | 600,000 | \$0 | 0 | D | |
| Employee Option Grant | \$1.34 | 06/30/2026 | | D ⁽¹⁾ | | | 700,000 | ⁽³⁾ | 01/17/2032 | Common Shares | 700,000 | \$0 | 0 | D | |
| Employee Stock Option ("Right to Buy") | \$4.37 | 06/30/2026 | | D ⁽¹⁾ | | | 343,000 | ⁽³⁾ | 01/04/2031 | Common Shares | 343,000 | \$0 | 0 | D | |
| Employee Option Grant | \$6.91 | 06/30/2026 | | D ⁽¹⁾ | | | 2,000,000 | ⁽³⁾ | 01/30/2030 | Common Shares | 2,000,000 | \$0 | 0 | D | |

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|--------------------------------------|--|--------------------------------|---|-----|---------|--|-----------------|---|----------------------------|--|--|---|--|
| | | | | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Stock Options (Right to Buy) | \$1.91 | 06/30/2026 | | D ⁽¹⁾ | | | 400,000 | (3) | 01/02/2029 | Common Shares | 400,000 | \$0 | 0 | D | |
| Employee Stock Option (Right to Buy) | \$1.14 | 06/30/2026 | | D ⁽¹⁾ | | | 100,000 | (3) | 03/28/2027 | Common Shares | 100,000 | \$0 | 0 | D | |
| Employee Stock Option (Right to Buy) | \$1.03 | 06/30/2026 | | D ⁽¹⁾ | | | 50,000 | (3) | 06/06/2027 | Common Shares | 50,000 | \$0 | 0 | D | |
| Employee Stock Option (Right to Buy) | \$2.8 | 06/30/2026 | | D ⁽¹⁾ | | | 300,000 | (3) | 01/19/2028 | Common Shares | 300,000 | \$0 | 0 | D | |
| Common Shares | \$3.07 | 06/30/2026 | | D ⁽¹⁾ | | | 400,000 | (3) | 01/22/2028 | Common Shares | 400,000 | \$0 | 0 | D | |

Explanation of Responses:

1. Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C\$2.41 per share.
2. Converted from Canadian price of C\$2.41 per share using an exchange rate of C\$1.4 = US\$1.00.
3. Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date.

Remarks:

TOTAL OPTIONS AND OPTION EXERCISE PRICE SUBJECT TO ADJUSTMENT AS A RESULT OF THE ISSUER'S 1:30 REVERSE STOCK SPLIT ON 2/26/25, AND THE ISSUER'S 1:15 REVERSE STOCK SPLIT ON 6/6/2023

/s/ William G. Rice

06/30/2026

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.